The Federal Trade Commission has approved a modified final order settling charges that Hikma Pharmaceuticals PLC’s acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. was anticompetitive.
Under the terms of the settlement, Hikma is required to divest assets related to five generic injectable drugs to Amphastar Pharmaceuticals, Inc., a California-based specialty pharmaceutical company that sells generic injectable and inhalation products.
Because Hikma and Amphastar adjusted the price that Amphastar paid for the divested assets after the Commission had accepted the consent agreement for public comment, the consent order has been modified to incorporate the revised divestiture agreement.
The Commission vote to approve the modified final order was 3-0-1, with Commissioner Brill not participating. (FTC File No. 151 0044; the staff contact is Jordan Andrew, Bureau of Competition, 202-326-3678)
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.